

Seeking Novel Leads in Rare Diseases and Neuroscience

Ipsen, a global biopharmaceutical company, is seeking **novel and innovative leads** to treat **rare disease and rare neuroscience disease indications**. A range of therapeutic areas and targets will be considered, but target diseases should be **rare** (>1.5 per million, <1 per 2,000).

A range of mechanisms-of-action and classes of molecules are of interest, with a particular focus on **small molecules, peptides, biologics, nucleic acids, RNA therapies** (i.e. siRNAs) and **antibody conjugates**. Ipsen is open to a variety of drug delivery methods.



Development Stage of Interest

Approaches of interest are preferred to be **clinical-stage assets** at **pre-IND, clinical phase I** or **clinical phase II**. Research should be **validated empirically**, e.g. through *in vitro* animal proof of concept studies.

Target Clinical Indications

The main areas of focus can be related to: **endocrinology, hepatic disease, inborn errors of metabolism, neuromuscular disease and musculoskeletal disease**.

A full list of diseases of interest can be accessed [here](#).

Out of Scope





- Ultra-rare diseases (<1.5 per million)
- Assets that treat rare dermatology, pulmonary, haematology, ophthalmology and infectious indications only
- Neurological diseases such as Alzheimer's, Parkinson's, multiple sclerosis, general pain and psychiatry
- Gene therapy, cell therapy, stem cell/regenerative therapies, vaccines, biosimilars/generic, traditional or herbal medicine, natural products, and medical devices
- Research-stage assets (unless clinic-ready or with empirical validation)

Submission Information

Submission of **one-page, 200-300 word** briefs are encouraged, along with any optional supplementary information e.g. relevant publications. Intellectual property status of the research should be included where relevant. Applicants are encouraged to fill in an **application form** to provide more in-depth information alongside their submission to this campaign. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Ipsen are seeking a variety of collaboration opportunities including asset acquisition and partnering, to be decided on a case-by-case basis.

Opportunities sought

-  Technologies
-  Research projects
-  Spinout companies
-  Biotech assets

Submissions

Please submit relevant, non-confidential opportunities online via: discover.in-part.com

Deadline: **24th April 2023 - 10:59 pm GMT**

Have any questions?

Contact our team at discover@in-part.co.uk

